Pembrolizumab Dual Endocrine Toxicity in a Metastatic Non-small Cell Lung Cancer Patient

Cureus 2026 Open access

Read full text
Authors: Sawsan Al-lababidi, Rand Alkhlaifat, Maria Herrera-Gonzalez, Darshi Sunderam
DOI: 10.7759/cureus.110075
Cited by: 1
References: 6

Abstract

Immune checkpoint inhibitors can cause endocrine toxicities, although involvement of multiple hormonal axes is uncommon. Hypophysitis associated with programmed death-1 inhibitors such as pembrolizumab may lead to life-threatening central adrenal insufficiency and can present diagnostic challenges. We present the case of a 58-year-old woman with metastatic non-small cell lung cancer who developed pembrolizumab-induced hypophysitis resulting in central adrenal insufficiency with delayed recognition, and concurrent immune-related thyroiditis.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies Advanced Breast Cancer Therapies

Publication details

Journal / source
Cureus
Publisher
Springer Science and Business Media LLC
Volume
18
Issue
6
Pages
e110075–e110075
Publication date
1 June 2026
Language
EN